Favrille Ends Specifid Follicular B-Cell NHL Vaccine Program After Phase III Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Specifid is the second vaccine candidate for follicular non-Hodgkin’s lymphoma to fail this year, following Genitope’s MyVax results in March.